Inactive Instrument

Emisphere Technologies, Inc. Stock

Equities

EMIS

US2913451066

Biotechnology & Medical Research

Dynamic Chart
Novo Nordisk A/S (CPSE:NOVO B) completed the acquisition of Emisphere Technologies, Inc.. CI
Novo Nordisk A/S : to boost pill-form diabetic drugs with $1.8 billion deal RE
Novo Nordisk A/S : to Buy Emisphere Technologies and Drug-Delivery Platform for $1.8 Billion DJ
Novo Nordisk A/S (CPSE:NOVO B) entered into a definitive agreement to acquire Emisphere Technologies, Inc. for $1.34 billion. CI
Emisphere Technologies, Inc. Announces Management Changes CI
Emisphere Technologies, Inc. Amends License Agreement with Novo Nordisk CI
Emisphere Technologies, Inc. Reports Unaudited Earnings Results for the First Quarter Ended March 31, 2017 CI
Emisphere Technologies, Inc. Auditor Raises 'Going Concern' Doubt CI
Emisphere Technologies, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2016 CI
Emisphere Restructures Debt Agreements CI
Emisphere Technologies, Inc. Announces Unaudited Earnings Results for the Third Quarter and Nine Months Ended September 30, 2016 CI
Emisphere Technologies, Inc. Announces Unaudited Earnings Results for the Second Quarter and Six Months Ended June 30, 2016 CI
Emisphere Technologies To Sell Eligen B12 CI
Emisphere Technologies, Inc. Appoints Alan Gallantar as Interim Chief Financial Officer CI
Emisphere Technologies, Inc. Announces Resignation of Michael R. Garone as Vice President & Chief Financial Officer, Effective June 25, 2016 CI
More news
Managers TitleAgeSince
Director of Finance/CFO - 14-12-31
Members of the board TitleAgeSince
Chairman 73 09-11-04
Director/Board Member 63 01-04-05
Director/Board Member 61 04-12-31
More insiders
Emisphere Technologies, Inc. is a commercial-stage pharmaceutical and drug delivery company. The Company, in partnership with pharmaceutical companies, develops new formulations of existing products, as well as new chemical entities, using its Eligen Technology. Its first prescription medical food product is oral Eligen B12. The Company utilizes its Eligen Technology to create new oral formulations of therapeutic agents. Its product pipeline includes prescription drug and medical food product candidates that are being developed in partnership or internally. Its preclinical programs focus on the development of oral formulations of potentially new treatments for diabetes and products in the areas of cardiovascular, appetite suppression and pain and on the development and potential expansion of nutritional supplement products. The Eligen Technology is an applicable oral drug delivery technology based on the use of synthetic chemical compounds known as Eligen delivery agents, or carriers.
More about the company